奥泰生物
(688606)
| 流通市值：53.33亿 | | | 总市值：53.33亿 |
| 流通股本：7928.09万 | | | 总股本：7928.09万 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 896,273,258.64 | 920,378,161.07 | 1,201,122,350.7 | 977,932,225.59 |
| 应收票据及应收账款 | 142,515,224.93 | 125,118,782.69 | 109,797,352.04 | 111,179,946.99 |
| 其中：应收票据 | - | 792,000 | - | - |
| 应收账款 | 142,515,224.93 | 124,326,782.69 | 109,797,352.04 | 111,179,946.99 |
| 预付款项 | 24,929,429.54 | 13,680,304.17 | 12,906,430.46 | 12,523,896.74 |
| 其他应收款合计 | 9,013,691.35 | 6,667,192.9 | 6,017,984.69 | 7,711,443.31 |
| 存货 | 162,001,788.31 | 160,321,121.43 | 152,694,357.23 | 160,288,048.74 |
| 其他流动资产 | 89,260,600.52 | 81,773,781.61 | 78,134,625.63 | 78,283,401.12 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 2,975,552,738.88 | 2,965,299,324.77 | 3,022,645,424.21 | 3,052,053,838.21 |
| 非流动资产: | | | | |
| 长期股权投资 | 61,500,631.65 | 41,583,105.01 | 22,012,709.53 | 21,833,957.89 |
| 其他权益工具投资 | 17,847,856.6 | 17,847,856.6 | 17,847,856.6 | 17,847,856.6 |
| 其他非流动金融资产 | 9,000,000 | 59,000,000 | 5,400,000 | 5,400,000 |
| 投资性房地产 | 55,034,667.42 | 48,659,082.58 | 13,435,637.7 | 13,526,900.1 |
| 固定资产 | 427,649,913.07 | 439,245,873.7 | 488,559,199.53 | 494,812,696.63 |
| 在建工程 | 507,356,411.4 | 459,922,387.7 | 428,628,542.03 | 402,663,243.57 |
| 使用权资产 | 3,545,226.61 | 4,267,070.79 | 8,959,644.12 | 10,599,397.56 |
| 无形资产 | 103,782,166.12 | 104,973,855.84 | 108,689,479.76 | 109,271,074.46 |
| 长期待摊费用 | 9,092,681.41 | 10,345,629.43 | 10,576,771.41 | 12,324,693.05 |
| 递延所得税资产 | 23,119,796.07 | 22,204,671.83 | 26,624,822.46 | 28,049,344.73 |
| 其他非流动资产 | 11,388,337 | 12,671,300 | 11,284,398 | 10,954,400 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 1,229,317,687.35 | 1,220,720,833.48 | 1,142,019,061.14 | 1,127,283,564.59 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 4,204,870,426.23 | 4,186,020,158.25 | 4,164,664,485.35 | 4,179,337,402.8 |
| 流动负债: | | | | |
| 交易性金融负债 | 28,692,361 | 28,724,990 | 28,631,715 | 33,018,098 |
| 应付票据及应付账款 | 68,181,755.02 | 104,799,237.87 | 100,613,428.66 | 112,165,910.31 |
| 应付账款 | 68,181,755.02 | 104,799,237.87 | 100,613,428.66 | 112,165,910.31 |
| 预收款项 | 1,314,605.23 | 515,312.09 | - | - |
| 合同负债 | 48,778,507.15 | 40,840,391.22 | 32,554,479.97 | 41,129,989.34 |
| 应付职工薪酬 | 10,589,387.91 | 27,616,044.79 | 26,003,240.48 | 25,692,603.19 |
| 应交税费 | 90,408,287.24 | 92,943,744.63 | 80,554,393.54 | 76,662,270.71 |
| 其他应付款合计 | 3,294,036.27 | 950,048.52 | 1,762,789.66 | 68,837,085.47 |
| 应付股利 | - | - | - | 66,124,264.5 |
| 一年内到期的非流动负债 | 2,676,951.62 | 2,336,630.68 | 3,940,968.05 | 4,492,081.7 |
| 其他流动负债 | 360,155.22 | 461,627.13 | 233,570.78 | 228,440.43 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 254,296,046.66 | 299,188,026.93 | 274,294,586.14 | 362,226,479.15 |
| 非流动负债: | | | | |
| 租赁负债 | 1,487,635.51 | 1,760,289.21 | 4,535,829.03 | 5,819,798.45 |
| 递延收益 | 1,390,200.58 | 1,640,265.11 | 1,900,184.64 | 2,160,104.17 |
| 递延所得税负债 | 11,274.11 | 11,274.11 | - | - |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 2,889,110.2 | 3,411,828.43 | 6,436,013.67 | 7,979,902.62 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 257,185,156.86 | 302,599,855.36 | 280,730,599.81 | 370,206,381.77 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 79,280,855 | 79,280,855 | 79,280,855 | 79,280,855 |
| 资本公积 | 1,711,025,473.26 | 1,707,661,785.48 | 1,720,311,310.31 | 1,719,863,795.56 |
| 减:库存股 | 113,011,953.53 | 113,011,953.53 | 137,864,852.82 | 140,336,281.71 |
| 其他综合收益 | 32,225,196.33 | 32,499,360.87 | 29,275,080.64 | 31,391,480.95 |
| 盈余公积 | 266,191,150.02 | 266,191,150.02 | 266,191,150.02 | 266,191,150.02 |
| 未分配利润 | 1,972,236,254.59 | 1,911,019,965.65 | 1,922,410,940.57 | 1,848,763,944.91 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 3,947,946,975.67 | 3,883,641,163.49 | 3,879,604,483.72 | 3,805,154,944.73 |
| 少数股东权益 | -261,706.3 | -220,860.6 | 4,329,401.82 | 3,976,076.3 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 3,947,685,269.37 | 3,883,420,302.89 | 3,883,933,885.54 | 3,809,131,021.03 |
| 负债和股东权益合计 | 4,204,870,426.23 | 4,186,020,158.25 | 4,164,664,485.35 | 4,179,337,402.8 |
| 公告日期 | 2025-04-29 | 2025-04-29 | 2024-10-31 | 2024-08-31 |
| 审计意见(境内) | | 标准无保留意见 | | |